Accelerated evaluation of CureVac vaccine begins in Europe

Photo: illustrative photo

The European Medicines Agency (EAL) has begun an accelerated evaluation of the Covid-19 vaccine produced by CureVac, according to the State Medicines Agency.

The decision to start the fast track is based on early results from clinical and non-clinical studies that the CureVac vaccine elicits an immune response against SAS-CoV-2.

The company is currently investigating the safety of the vaccine and how well it elicits an immune response to the virus. The fast track assessment will continue until the agency has received sufficient data to begin official registration.

CureVac may be the third vaccine based on the innovative mRNA technology. That is, the vaccine contains mRNA molecules, which contain instructions for creating the s-protein of the coronavirus, which allows the virus to enter cells. Thus, the immune system will learn to recognize the new coronavirus and will be ready to defend itself when it encounters a real virus.

Accelerated vaccine evaluation means the agency evaluates data as it becomes available, rather than waiting for all phases of research to be completed. This allows for faster completion of the assessment procedure without compromising quality.

Latvia plans to receive the first batch of CureVac vaccine in the second quarter of this year. The total order quantity is 231,316 doses. In the third quarter Latvia expects 210 414 doses of the vaccine, and in the last quarter 252 440 doses. In 2022, it is still planned to receive another 252,340 doses of the vaccine.

By the way, as of Friday morning, February 12, 93,000 residents of Latvia have already signed up for the Covid-19 vaccine, about 20,000 of them are people over 60 years old.

Source: RSS by

*The article has been translated based on the content of RSS by If there is any problem regarding the content, copyright, please leave a report below the article. We will try to process as quickly as possible to protect the rights of the author. Thank you very much!

*We just want readers to access information more quickly and easily with other multilingual content, instead of information only available in a certain language.

*We always respect the copyright of the content of the author and always include the original link of the source article.If the author disagrees, just leave the report below the article, the article will be edited or deleted at the request of the author. Thanks very much! Best regards!